{
    "organizations": [],
    "uuid": "cba2d8a23ce30d9e9e5db51d9cb54c75c9c795a1",
    "author": "",
    "url": "https://www.reuters.com/article/brief-bristol-myers-says-fda-approves-op/brief-bristol-myers-says-fda-approves-opdivo-yervoy-combo-for-treating-patients-with-renal-cell-carcinoma-idUSASC09VZ4",
    "ord_in_thread": 0,
    "title": "BRIEF-Bristol-Myers Says FDA Approves Opdivo + Yervoy Combo For Treating Patients With Renal Cell Carcinoma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 16, 2018 / 7:42 PM / Updated 19 minutes ago BRIEF-Bristol-Myers Says FDA Approves Opdivo + Yervoy Combo For Treating Patients With Renal Cell Carcinoma Reuters Staff 1 Min Read \nApril 16 (Reuters) - Bristol-Myers Squibb Co: \n* U.S. FOOD AND DRUG ADMINISTRATION APPROVES OPDIVO® (NIVOLUMAB) + YERVOY® (IPILIMUMAB) COMBINATION AS FIRST-LINE TREATMENT FOR PATIENTS WITH INTERMEDIATE- AND POOR-RISK ADVANCED RENAL CELL CARCINOMA \n* BRISTOL-MYERS SQUIBB - IN PHASE 3 CHECKMATE -214 CLINICAL TRIAL, OPDIVO + YERVOY COMBINATION DEMONSTRATED A SIGNIFICANT INCREASE IN OVERALL SURVIVAL \n* BRISTOL-MYERS SQUIBB - IN PHASE 3 CHECKMATE -214 TRIAL, OPDIVO + YERVOY ALSO DELIVERED DURABLE RESPONSES, WITH HIGHER OBJECTIVE RESPONSE RATE VERSUS SUNITINIB Source text for Eikon: Further company coverage:",
    "published": "2018-04-16T22:42:00.000+03:00",
    "crawled": "2018-04-16T23:11:11.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "say",
        "fda",
        "approves",
        "opdivo",
        "yervoy",
        "combo",
        "treating",
        "patient",
        "renal",
        "cell",
        "carcinoma",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "squibb",
        "co",
        "food",
        "drug",
        "administration",
        "approves",
        "nivolumab",
        "ipilimumab",
        "combination",
        "treatment",
        "patient",
        "advanced",
        "renal",
        "cell",
        "carcinoma",
        "squibb",
        "phase",
        "checkmate",
        "clinical",
        "trial",
        "opdivo",
        "yervoy",
        "combination",
        "demonstrated",
        "significant",
        "increase",
        "overall",
        "survival",
        "squibb",
        "phase",
        "checkmate",
        "trial",
        "opdivo",
        "yervoy",
        "also",
        "delivered",
        "durable",
        "response",
        "higher",
        "objective",
        "response",
        "rate",
        "versus",
        "sunitinib",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}